BioSpace News Archive

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.

Sonendo, Inc. announced that, on November 15, 2023, it received a notice from the New York Stock Exchange that the Company was no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the Company’s average global market capitalization over a consecutive 30 trading-day period being less than $50 million and its stockholders’ equity being less than $50 million.

Baird Medical Devices, Inc. today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the U.S. Food and Drug Administration (the “FDA”) under Section 510 (K) to begin marketing its portfolio of Microwave Ablation Systems and Disposable Microwave Ablation Needles as regulatory Class II devices in the United States.

Acadia Pharmaceuticals Inc. announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

Innovent Biologics, Inc. announces that full results from a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes were published in Diabetes Care.

Immix Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101).

InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023.

Samsung will feature the latest innovation in cutting-edge mobile computed tomography, including the state-of-the-art OmniTom Elite with Photon Counting Detector (PCD) technology.

Throughout 2022, we deployed new staff training and development programs that are customer-centric and emphasize thoughtful and patient-focused care delivery.